S44 Aggressive Pituitary Adenomas: Therapeutic Challenges and Hope for the Future

Program: Symposia
Clinical/Translational Session
Sunday, April 3, 2016: 8:15 AM-9:45 AM
BR East (BCEC)
Chair:
Philippe Chanson, MD, Univ Paris-Sud, UMR-S693, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France

Disclosures:
PC: Clinical Researcher, Pfizer, Inc., Clinical Researcher, Ipsen, Clinical Researcher, Novartis Pharmaceuticals.
8:15 AM
Sylvia L. Asa, MD, PhD, Pathology, University Health Network, Toronto, ON, Canada
Nothing to Disclose: SLA
8:45 AM
Gérald Raverot, MD, PhD, Federation d'Endocrinologie du Pole Est, Hospices Civils de Lyon, Lyon Cedex 03, France
Nothing to Disclose: GR
9:15 AM
Anthony P Heaney, MD, PhD, Divisions of Endocrinology and Neurosurgery, Departments of Medicine and Surgery, David Geffen School of Medicine, University of California (UCLA), Los Angeles, CA
Disclosures:
APH: Coinvestigator, Novartis Pharmaceuticals, Advisory Group Member, Novo Nordisk.
See more of: Symposia

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire